AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

First generation EGF receptor tyrosine kinase inhibitors (EGFR TKIs) provide significant clinical benefit in patients with advanced EGFR mutant (EGFRm+) non-small cell lung cancer (NSCLC). Patients ultimately develop disease progression, often driven by acquisition of a second T790M EGFR TKI resista...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Discov
Main Authors: Cross, Darren A. E., Ashton, Susan E., Ghiorghiu, Serban, Eberlein, Cath, Nebhan, Caroline A., Spitzler, Paula J., Orme, Jonathon P., Finlay, M. Raymond V., Ward, Richard A., Mellor, Martine J., Hughes, Gareth, Rahi, Amar, Jacobs, Vivien N., Brewer, Monica Red, Ichihara, Eiki, Sun, Jing, Jin, Hailing, Ballard, Peter, Al-Kadhimi, Katherine, Rowlinson, Rachel, Klinowska, Teresa, Richmond, Graham H. P., Cantarini, Mireille, Kim, Dong-Wan, Ranson, Malcolm R., Pao, William
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4315625/
https://ncbi.nlm.nih.gov/pubmed/24893891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0337
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki